Pacira BioSciences, Inc.
PCRX
$23.04
$0.200.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 734.86M | 726.41M | 716.79M | 705.85M | 702.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 734.86M | 726.41M | 716.79M | 705.85M | 702.77M |
| Cost of Revenue | 157.36M | 155.25M | 149.34M | 153.92M | 157.32M |
| Gross Profit | 577.51M | 571.16M | 567.46M | 551.93M | 545.45M |
| SG&A Expenses | 375.93M | 368.76M | 346.77M | 329.30M | 308.85M |
| Depreciation & Amortization | 57.29M | 57.29M | 57.29M | 57.29M | 57.29M |
| Other Operating Expenses | -- | 351.00K | 351.00K | 351.00K | 351.00K |
| Total Operating Expenses | 710.26M | 698.61M | 657.15M | 637.41M | 612.49M |
| Operating Income | 24.60M | 27.80M | 59.65M | 68.44M | 90.29M |
| Income Before Tax | 13.17M | 16.87M | 41.83M | -106.55M | -68.04M |
| Income Tax Expenses | 8.03M | 9.84M | 20.39M | 20.91M | 35.69M |
| Earnings from Continuing Operations | 5.14 | 7.03 | 21.44 | -127.46 | -103.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.14M | 7.03M | 21.44M | -127.46M | -103.73M |
| EBIT | 24.60M | 27.80M | 59.65M | 68.44M | 90.29M |
| EBITDA | 115.79M | 118.83M | 145.07M | 158.43M | 171.81M |
| EPS Basic | 0.13 | 0.16 | 0.47 | -2.77 | -2.25 |
| Normalized Basic EPS | 0.21 | 0.31 | 0.78 | 0.84 | 1.29 |
| EPS Diluted | 0.12 | 0.15 | 0.44 | -2.79 | -2.29 |
| Normalized Diluted EPS | 0.21 | 0.31 | 0.75 | 0.81 | 1.23 |
| Average Basic Shares Outstanding | 172.45M | 178.26M | 181.94M | 184.04M | 184.75M |
| Average Diluted Shares Outstanding | 173.81M | 179.43M | 185.48M | 187.16M | 192.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |